Clinical trials: Severe Pneumonia
Severe Community-Acquired Pneumonia (sCAP), Elderly Infection
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients
The ESCAPE 10 study is a multinational, retrospective, observational cohort study that aims to investigate the epidemiology and outcome determinants of severe community-acquired pneumonia (sCAP) in elderly patients (≥65 years).
- Conditions
- Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation
- Trial name
- ESCAPE10 (NCT07070284)
- Where
- 18 sites in Croatia, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Joan Sabater-Riera
SARS-CoV-2 Infection
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
The study RECOVER is a randomized, open-label, multicenter phase II trial, designed to assess the clinical outcome of SARS-CoV-2 disease in high-risk patients (group 1 to group 4) following treatment with anti-SARS-CoV-2…
- Trial name
- RECOVER (NCT05200754)
- Testing
- Convalescent/Vaccine-boosted Plasma (CP/PVP)
- Where
- 16 sites in Germany
- Volunteers
- 174 people
- Sponsor
- Carsten Müller-Tidow
Covid19, Severe Acute Respiratory Syndrome
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
This phase 1 trial aims to assess the safety and tolerability of two doses of ABNCoV2, formulated with and without the adjuvant MF59, in healthy adult volunteers and to identify the dosage and formulation that optimizes the…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection
- Trial name
- COUGH-1 (NCT04839146)
- Testing
- ABNCoV2 Vaccine
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Covid19
Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
Primary objectives Part 1: To evaluate the safety and tolerability of COR-101 compared to placebo Secondary objectives Part 1: To evaluate the preliminary efficacy of COR-101 compared to placebo in hospitalized patients with…
- Trial name
- NCT04674566
- Testing
- COR-101
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Corat Therapeutics Gmbh
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization
The principal aim of this interventional, multicentre study is to compare the impact of a follow-up by monthly telephone dietetic consultations, started 3 months after discharge from hospital, for a period of 3 months, on the…
- Trial name
- COVINUT (NCT04933929)
- Testing
- Post-hospitalization nutritional monitoring
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Gérond'if
COVID-19, Intensive Care Unit
Zooming in on Cerebral Abnormalities in Severely Affected COVID-19 Patients
Brain injury is one of the complications in COVID-19 intensive care unit (ICU) survivors, though the precise underlying mechanism is unclear.
- Trial name
- ZoomCOVID (NCT05197296)
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht University Medical Center
Coronavirus Disease 2019, Character of the Severe Patients
The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19
To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory…
- Trial name
- NCT04403009
- Testing
- no intervention
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Pneumonia
A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Part 1 of this trial enrolled 30 patients to receive Auxora (formerly CM4620) in a 2:1 randomized, open label trial of patients with severe and critical COVID-19 pneumonia.
- Trial name
- NCT04345614
- Testing
- Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2)
- Where
- 17 sites in United States
- Volunteers
- 314 people
- Sponsor
- CalciMedica, Inc.
Severe Pneumonia, Special Disease Cohort Database
Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia
The incidence rate and mortality of lung infection are high worldwide. It is a common and frequently occurring disease which seriously threatens human health. Severe pneumonia accounts for 18-36% of all pneumonia.
- Conditions
- Severe Pneumonia, Special Disease Cohort Database, Holographic Library of Biological Samples
- Trial name
- NCT04882436
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Ruijin Hospital
Coronavirus Disease 2019 (COVID-19)
Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency
In this prospective observational study we aim to study the association of vitamin D deficiency with adverse clinical outcomes in patients infected with Coronavirus disease 2019
- Trial name
- COVIT-D (NCT04403932)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital San Carlos, Madrid
COVID-19
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been…
- Trial name
- NCT04429711
- Testing
- Ivermectin Oral Product
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Covid19
Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
Study to compare the efficacy and safety of colchicine and glucocorticoids compared with the standard of treatment for moderate/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a…
- Trial name
- NCT04492358
- Testing
- Colchicine, Prednisone tablet, standard of care
- Where
- 3 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Maria Joyera Rodríguez
COVID-19
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
- Trial name
- NCT04432298
- Testing
- Pamrevlumab
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kyntra Bio
Covid19, SARS-CoV Infection
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.
- Trial name
- DAWN (NCT04730206)
- Testing
- Camostat, Molnupiravir
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- KU Leuven
Covid-19
Characterization in 18F-FDG PET-CT of Brain and Lung Lesions in Subjects With a History of Severe COVID-19
Patients with Covid-19 (Coronavirus disease 19) may experience multiple neurological symptoms . 18F-FDG PET-CT ( Positons EmissionTomography coupled with a Computer Tomography with flurodesoxyglucose labelled with fluor 18)…
- Trial name
- TEP-COV (NCT04764721)
- Testing
- 18F-FDG PET-CT
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19 Pneumonia
Bevacizumab in Patients With Severe Covid-19
The novel coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which causes epidemic worldwide. Novel coronavirus disease (COVID-19) causes acute lung injury (ALI) and acute respiratory distress…
- Trial name
- BEST (NCT04305106)
- Testing
- Bevacizumab, Standard care
- Where
- China
- Volunteers
- 588 people
- Sponsor
- Qilu Hospital of Shandong University
COVID-19
Azithromycin in Hospitalized COVID-19 Patients
The present study is a randomized, double-blind, controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Shahid Modarres Medical…
- Trial name
- AIC (NCT04359316)
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
COVID-19, Acute Respiratory Distress Syndrome
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- SINK COVID-19 (NCT04365985)
- Testing
- Naltrexone, Ketamine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Corewell Health East
Childhood Severe Illness, Pneumonia
Tools for the Integrated Management of Childhood Illness: Cross-country Quasi-experimental Pre-post Study in Kenya and Senegal
By introducing pulse oximetry, with or without clinical decision support algorithms, to primary care facilities in India, Kenya, Senegal and Tanzania, the Tools for Integrated Management of Childhood Illness (TIMCI) project aims…
- Conditions
- Childhood Severe Illness, Pneumonia, Primary Health Care, Hypoxia
- Trial name
- TIMCI (NCT05065320)
- Where
- 2 sites in Kenya, Senegal
- Volunteers
- 51,590 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Covid-19, Cytokine Storm
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells.
- Trial name
- NCT04753476
- Testing
- Injection of Secretome-MSCs, Standard treatment of Covid-19
- Where
- 6 sites in Indonesia
- Volunteers
- 48 people
- Sponsor
- Stem Cell and Cancer Research Indonesia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.